Healthcare stocks were mixed pre-bell Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.1% and the iShares Biotechnology ETF (IBB) 0.3% higher.
Tempus AI (TEM) shares were up more than 6% after the company said it has received approval from the US Food and Drug Administration for a tumor-only indication for its xT CDx next-generation sequencing platform used for comprehensive genomic profiling of solid tumors.
Agios Pharmaceuticals (AGIO) stock was down more than 3% after the company said it will discontinue development of tebapivat for lower-risk myelodysplastic syndromes after a phase 2b study failed to meet the company's threshold for further advancement.
Natera (NTRA) shares were up more than 1% after the company said Diakonos Oncology will use its Signatera test to assess molecular response in patients with refractory melanoma enrolled in its DOC-RM phase I/II investigational immunotherapy trial.